Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1
- PMID: 7584083
Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1
Abstract
The tat gene product (Tat) of HIV-1 is an early regulatory protein necessary for viral gene expression and replication. Tat may also play a role as an extracellular protein in both HIV-1 replication and AIDS-associated disorders such as Kaposi's sarcoma. Thus, Tat represents a good target for gene therapy against AIDS. Here we show that when vectors expressing antisense tat RNA are transiently transfected into CD4+ cells, they block about 70% of HIV-1 replication and inhibit the rescue of Tat-defective HIV-1 proviruses by inhibition of Tat protein expression and consequent lack of transcriptional activation of the HIV-promoter. However, antisense tat vectors cannot block the activity of extracellular Tat protein. Another tat inhibitory construct (poly-Tat-activation response; TAR) previously suggested to inhibit HIV-1 transactivation by sequestering the Tat protein, inhibited the activity of extracellular Tat, but like antisense tat RNA did not completely block viral gene expression and replication. These results suggested that one mode of inhibition is not sufficient to block Tat function. However, when the antisense tat and the poly-TAR constructs were combined HIV-1 gene expression was completely blocked (94-98%), suggesting that a combination of inhibitory genes blocking Tat by sequential steps may be a better approach for AIDS gene therapy.
Similar articles
-
Antitat gene therapy: a candidate for late-stage AIDS patients.Gene Ther. 1995 May;2(3):218-22. Gene Ther. 1995. PMID: 7614253
-
Inhibition of HIV-1 in CEM cells by a potent TAR decoy.Gene Ther. 1995 Aug;2(6):377-84. Gene Ther. 1995. PMID: 7584112
-
High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.Gene Ther. 1998 Dec;5(12):1665-76. doi: 10.1038/sj.gt.3300780. Gene Ther. 1998. PMID: 10023446
-
The AIDS virus. What we know and what we can do about it.West J Med. 1991 Nov;155(5):481-7. West J Med. 1991. PMID: 1687714 Free PMC article. Review. No abstract available.
-
Progress towards gene therapy for HIV infection.Gene Ther. 1994 Jan;1(1):13-26. Gene Ther. 1994. PMID: 7584055 Review.
Cited by
-
Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.Ann Hematol. 1995 Aug;71(2):89-95. doi: 10.1007/BF01699252. Ann Hematol. 1995. PMID: 7544629
-
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.J Immunol. 2009 Mar 15;182(6):3718-27. doi: 10.4049/jimmunol.0803115. J Immunol. 2009. PMID: 19265150 Free PMC article.
-
Gene therapy for HIV.Sex Transm Infect. 2001 Apr;77(2):93-6. doi: 10.1136/sti.77.2.93. Sex Transm Infect. 2001. PMID: 11287684 Free PMC article. Review. No abstract available.
-
HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.BMC Infect Dis. 2016 Aug 22;16(1):442. doi: 10.1186/s12879-016-1724-7. BMC Infect Dis. 2016. PMID: 27549342 Free PMC article.
-
Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.J Investig Med. 2014 Oct;62(7):914-9. doi: 10.1097/JIM.0000000000000103. J Investig Med. 2014. PMID: 25118114 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials